Real World Effectiveness of fixed combination of glargine 100 U/ml and lixisenatide therapy in outpatients with Type 2 Diabetes: A Retrospective Cohort Study SOLO

Real World Effectiveness of fixed combination of glargine 100 U/ml and lixisenatide therapy in outpatients with Type 2 Diabetes: A Retrospective Cohort Study SOLO

Background: The effectiveness and safety of a fixed combination of insulin glargine 100 ME/ml and lixisenatide for treatment of patients with type 2 diabetes (T2DM) has been demonstrated in randomized clinical trials, but there are still not enough data of it`s usage of it real clinical practice.Aim...

Full description

Saved in:

Bibliographic Details
Main Authors:	M. B. Antsiferov, N. A. Demidov, M. A. Balberova, T. I. Safronova, O. A. Mishra, S. G. Magomedova
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2022-05-01
Series:	Сахарный диабет
Subjects:	fixed combination of insulin glargine 100 me/ml and lixisenatide type 2 diabetes glargine lixisenatide
Online Access:	https://www.dia-endojournals.ru/jour/article/view/12809
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prescription characteristics of the insulin glargine plus lixisenatide fixed-ratio combination in real-world clinical practice according to the Registry of Diabetes Mellitus in the Moscow Region
by: Inna V. Misnikova, et al.
Published: (2024-12-01)

Real-world effectiveness and safety of fixed-ratio combination insulin glargine 100 u/ml plus lixisenatide in adults with type 2 diabetes (T2DM): subanalysis of the international, multicentre, prospective observational study SUCCESS in the Russian population
by: O. K. Vikulova, et al.
Published: (2024-11-01)

Priority areas in management of diabetes mellitus type 1 & 2 (following 47th EASD Annual Meeting)
by: Ivona Renata Yarek-Martynova, et al.
Published: (2011-12-01)

On the safety of insulin Glargine
by: Ivan Ivanovich Dedov, et al.
Published: (2009-09-01)

Development and Validation of Approach for the Detection of Neutralizing Antibodies Against Insulin (Glargine) in Human Blood Plasma
by: N. B. Abramenko, et al.
Published: (2019-09-01)

Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study
by: Elena Valer'evna Biryukova, et al.
Published: (2012-09-01)

Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review
by: Juliana West, et al.
Published: (2025-04-01)

Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506)
by: Marina Vladimirovna Shestakova, et al.
Published: (2010-03-01)

Adverse drug events associated with insulin glargine: a real-world pharmacovigilance study based on the FAERS database
by: Tongtong Wang, et al.
Published: (2025-04-01)

Insulin Glargine Biosimilar Prescribing and Cost Trends in the United Kingdom’s Primary Care from 2020 to 2024
by: Murtada Alsaif, et al.
Published: (2025-06-01)

Individualisation of basal insulin therapy of type 2 diabetes: evidence from large randomized controlled trials
by: S. V. Nedogoda, et al.
Published: (2023-01-01)

Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
by: Vadim Valer'evich Klimontov, et al.
Published: (2014-12-01)

Mauriac syndrome in adult with type 1 diabetes mellitus
by: Natalya Alexandrovna Molitvoslovova, et al.
Published: (2011-09-01)

Risk of oncological diseases in patients with diabetes mellitus
by: Gagik Radikovich Galstyan
Published: (2009-12-01)

Lantus, the first peakless basal insulin analogue: 10 years of clinical experience in children and adolescents
by: Tamara Leonidovna Kuraeva
Published: (2014-07-01)

Survival following intentional overdose of veterinary insulin: A case report
by: Elsa Sandeno, et al.
Published: (2025-12-01)

Risk of Hearing Loss in Patients Treated with Exendin-4 Derivatives: A Network Meta-Analysis of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors
by: Jiann-Jy Chen, et al.
Published: (2025-05-01)

COMPARATIVE STUDY OF INTERACTION OF SOME DOMESTIC HUMAN INSULIN SUBSTANCES AND ITS ANALOGUES WITH INSULIN RECEPTOR BY METHOD OF SURFACE PLASMON RESONANCE
by: I. N. Urakova, et al.
Published: (2019-01-01)

Impact of switching from neutral protamine hagedorn insulin (NPH) to glargine insulin on glycemic control and clinical outcomes in pediatric patients with type 1 diabetes
by: Hiba Abdelmunim Suliman Elsheikh, et al.
Published: (2025-06-01)

Evaluation of biosimilarity of RinGlar® (GEROPHARM LLC, Russia) and Lantus® (Sanofi-Aventis Deutschland GmbH, Germany) using the euglycemic hyperinsulinemic clamp technique in patients with type 1 diabetes: double-blind randomized clinical trial
by: Alexander Y. Mayorov, et al.
Published: (2020-12-01)

Basal insulin therapy in patients with type 2 diabetes mellitus and poor control of glycemia by oral hypoglycemic agents: results of direct comparative study of insulin analogs Lantus and Levemir
by: Alsu Gafurovna Zalevskaya, et al.
Published: (2010-06-01)

Effects of GLP-1RAs on cardiovascular outcomes in patients with type 2 diabetes mellitus: review of real-world data on target populations from diabetes registry in Russian Federation
by: O. K. Vikulova, et al.
Published: (2022-03-01)

Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world
by: George Dailey, et al.
Published: (2019-05-01)

Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature
by: Hernando Vargas-Uricoechea
Published: (2018-01-01)

Microcontroller-Based EdgeML: Health Monitoring for Stress and Sleep via HRV
by: Priyanshu Srivastava, et al.
Published: (2024-12-01)

S-100 PROTEIN EXPRESSION LEVELS AS A POTENTIAL PROGNOSTIC MARKER IN NEUROBLASTOMA
by: Gamze Sanlav, et al.
Published: (2022-08-01)

Enhancing drilling performance in 3D printed PLA implants application of PIV and ML models
by: K Shunmugesh, et al.
Published: (2025-04-01)

The effects of bromazepam on the early stage of visual information processing (P100) Efeitos do bromazepam no estágio inicial do processamento de informação visual (P100)
by: Fernanda Puga, et al.
Published: (2007-12-01)

S100B protein related neonatal hypoxia Relação da proteína S100B com a hipóxia neonatal
by: Régis Osorio Martins, et al.
Published: (2006-03-01)

BIST 100 Endeksi Borsa İstanbul’un Genel Performansını Yansıtıyor mu?
by: Yasemin Yurtoğlu, et al.
Published: (2024-12-01)

Prognostic Value of Protein S100B in Traumatic Brain Injury
by: Marwa Elsayed Abdelfattah, et al.
Published: (2021-01-01)

Prognostic value of serum S100B concentration in patients with acute spontaneous supratentorial intracerebral hemorrhage
by: О. A. Koziolkin, et al.
Published: (2021-05-01)

In Vitro Determine the Cytotoxicity of Cerium Oxide Nanoparticles Against HBL-100 and ‎Rat’s Embryonic Fibroblast (REF) Cell Lines
by: Sundus Jaffar Razak, Ali A.A. Al-Ali
Published: (2025-03-01)

TinyML with Meta-Learning on Microcontrollers for Air Pollution Prediction
by: I Nyoman Kusuma Wardana, et al.
Published: (2024-04-01)

Smart Lighting Systems: State-of-the-Art in the Adoption of the EdgeML Computing Paradigm
by: Gaetanino Paolone, et al.
Published: (2025-02-01)

Calibração de sensores tipo PT100 com fornos tipo bloco seco
by: William Fagundes De Farias, et al.
Published: (2025-01-01)

Ob 100 letnici izobraževanja medicinskih sester v Sloveniji
by: Brigita Skela Savič
Published: (2024-12-01)

Intraperitoneal Administration of S100A8 Ameliorates Experimental Acute Colitis in Rats
by: Kano Matsuo, et al.
Published: (2024-11-01)

Advances in S100 protein family for gynecological malignancies
by: Shenglong Wu, et al.
Published: (2025-03-01)

Empowering Healthcare: TinyML for Precise Lung Disease Classification
by: Youssef Abadade, et al.
Published: (2024-10-01)